Nanodisc, Inc. Company Profile

02:16 EDT 24th March 2018 | BioPortfolio

Nanodisc, Inc. owns an exclusive, world-wide commercial license to all applications of Nanodiscs™ – nano scale, discoidal structures composed of specially engineered proteins and phospholipid bilayers. “Nanodiscs™ were discovered and developed by Dr. Sligar, Company Co-Founder, Professor at University of Illinois at Urbana Champaign and a principal investigator in the federally funded Nanotechnology Center (NSEC) at Northwestern University. Nanodiscs™ offer pharmaceutical researchers and developers a vastly superior way to work with “cell membrane-associated molecules” (such as receptors, ion channels and enzymes), generally amphipathic molecules which offer exciting potential as drugs and drug targets but which are difficult and expensive to study with traditional methods. Because Nanodiscs™ offer naturalistic presentation of target molecules in a soluble form, they allow scientists to study and use membrane proteins in whole new ways to discover drugs. Naturalistic presentation and solubility also support the creation of novel therapeutics utilizing or consisting partly of Nanodiscs. The Company’s current technology allows the manufacture of Nanodiscs™ achieving industrial scale at extremely low cost with excellent precision.



News Articles [0 Results]


Drugs and Medications [0 Results]


PubMed Articles [12 Associated PubMed Articles listed on BioPortfolio]

Reconstitution of Membrane Proteins into Nanodiscs for Single-Particle Electron Microscopy.

The structure determination of integral membrane protein (IMP) in lipid environment is particularly challenging. Among emerging methods for exchanging detergent required for IMP purification by origin...

High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia.

Therapeutic strategies using endogenous stem cell mobilizer can provide effective cell-free therapy for addressing various ischemic diseases. In particular, substance P (SP) exhibited therapeutic rege...

Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy.

While cancer immunotherapy provides new exciting treatment options for patients, there is an urgent need for new strategies that can synergize with immune checkpoint blockers and boost the patient res...

pH resistant monodispersed polymer-lipid nanodiscs.

Polymer lipid nanodiscs have provided an invaluable system for structural and functional studies of membrane proteins in their near-native environment. In spite of the recent advances in the developme...

SecY-SecA fusion protein retains the ability to mediate protein transport.

In bacteria, the membrane protein complex SecY/E/G and SecA ATPase are essential for protein translocation. About 30% of newly synthesized proteins in the cytosol are targeted to and translocated acro...

Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Nanodisc, Inc.

Nanodisc, Inc. owns an exclusive, world-wide commercial license to all applications of Nanodiscs™ – nano scale, discoidal structures composed of specially engineered proteins and phosphol...

More Information about "Nanodisc, Inc." on BioPortfolio

We have published hundreds of Nanodisc, Inc. news stories on BioPortfolio along with dozens of Nanodisc, Inc. Clinical Trials and PubMed Articles about Nanodisc, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nanodisc, Inc. Companies in our database. You can also find out about relevant Nanodisc, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Corporate Database Quicklinks

Searches Linking to this Company Record